Researchers have developed a non-invasive method to reduce movement disorders in Parkinson’s disease patients by applying overlapping electrical currents to the scalp. This technology reaches deep into the brain without the need for surgery, and there is a noticeable improvement in slowness and tremors for at least an hour after one session. These results were published in a peer-reviewed journal. e-biomedicine.
Parkinson’s disease is a progressive neurological disease that affects movement and body coordination. People with this disorder often experience tremors, muscle stiffness, and an overall slowness of movement known as bradykinesia. These symptoms result from pathological changes in the brain’s basal ganglia, a group of structures located deep in the cerebral cortex that help control voluntary movements. One particular structure within this network is the subthalamic nucleus, which plays a central role in regulating motor function.
For patients with advanced symptoms, doctors may recommend an invasive procedure known as deep brain stimulation. This surgery involves making small holes in the skull and implanting permanent metal electrodes directly into areas such as the subthalamic nucleus. Electrical impulses from a pacemaker-like device regulate abnormal brain activity and reduce movement difficulties. This surgery has inherent physical risks such as infection and bleeding within the brain, and requires ongoing management of the implanted hardware.
Because of the risks and high economic costs of these surgeries, less than 3 percent of the world’s population with Parkinson’s disease receives deep brain stimulation. Medical professionals need alternative therapies that can target the same deep brain regions without damaging the brain itself. A relatively new technique called transcranial temporal interference stimulation provides a potential solution to this problem.
This method uses two sets of temporary electrodes placed on the outside of the head to deliver a high-frequency electrical current. These high-frequency fields pass through brain tissue without altering cellular activity themselves. When two electric fields intersect deep within the brain, new low-frequency waves are generated precisely at the point of intersection. This newly formed wave pulses at a slow enough rate to affect the behavior of brain cells in the target area without affecting the surface of the brain at all.
The research team sought to determine whether this technology could safely target the subthalamic nucleus to reduce motor symptoms. The study was led by Chenhao Yang, a researcher at the Key Laboratory of Exercise and Health Sciences at Shanghai Sports University in China, and colleagues from several international academic institutions. The research team wanted to know if this customized single session of electrotherapy could be tolerated by patients and if it resulted in measurable improvements in body movement.
To answer these questions, the research group recruited 30 adults with early to mid-stage Parkinson’s disease. All participants were able to walk without assistance and had maintained stable medication habits for at least 4 weeks prior to the study. Before starting the experiment, each person underwent a magnetic resonance imaging scan of their brain. The researchers used these detailed scans to build individual computer models of each person’s cranial anatomy.
These personalized models allowed scientists to calculate the precise placement of scalp electrodes needed to direct an electric field into each individual’s subthalamic nucleus. The researchers set the device to generate a specific frequency difference of about 130 hertz at a crossroads deep in the brain. They chose this particular frequency because it matches the standard electrical rhythms utilized in traditional surgical deep brain stimulation.
The trial used a randomized, double-blind, crossover design, with all participants experiencing both the real and sham treatments on separate days. The sham treatment, or sham treatment, served as a baseline comparison for the scientists. During the sham session, the device delivered an electrical current to the scalp that recreated a mild tingling sensation, but did not generate waves that crisscrossed deep in the brain. Neither the participants nor the staff performing the clinical assessment knew which version was being administered that day.
On the day of the experiment, participants refrained from taking their usual Parkinson’s medication for at least 12 hours. They then received either the real brain stimulation or a sham version for 20 minutes while resting in a chair. A certified clinical examiner assessed each participant’s motor performance using a standardized motor symptom rating scale. These formal evaluations were conducted just before turning on the machine, immediately after the end of the 20 minutes, after 30 minutes, and a full hour after the end of the session.
The evaluation showed clear differences between the two test conditions. After the actual temporal interference stimulus, 70% of participants experienced a clinically meaningful reduction in motor symptoms. After sham treatment, only 15% of volunteers reached the same threshold of improvement. The real stimulus had a greater overall reduction in motor symptom scores compared to the sham treatment at each time point checked after the machine was turned off.
When analyzing specific physical symptoms, the researchers found that slowness of movement and resting tremors showed the greatest improvement. These benefits were immediately apparent and persisted throughout the 1-hour observation. Changes in muscle stiffness and overall postural balance were less consistent across groups, with some of the improvements in stiffness becoming apparent at 60 minutes.
This procedure also proved to be safe and well tolerated by volunteers. No serious adverse events occurred during visits to either clinic. Mild side effects, such as temporary scalp tingling or warmth, occurred at similar rates regardless of whether people received the real or sham treatment. The lack of difference in noxious physical sensations was not statistically significant, as most participants could not accurately guess the treatment they received, which helped ensure that the blinding process worked.
“One of the most promising aspects of this study is the ability to individualize stimulation based on each patient’s own brain anatomy,” said Brad Manners, senior research scientist at Hebrew Senior Life’s Hinda and Arthur Marcus Institute on Aging. He explained that “this level of precision may become increasingly important as we learn how to tailor neuromodulatory therapies to different Parkinson’s disease symptoms and different patients.”
Although early data shows promise, the research team acknowledged some limitations to the current study. The study involved a relatively small number of participants, all of whom were of Asian descent, and most of whom were women. This limited demographic profile means that the results may not automatically apply to other populations with different cranial anatomy or different genetic backgrounds. The researchers noted that multicenter trials involving more diverse groups of people are needed to confirm these initial observations.
Another limitation is that the researchers rely entirely on computer modeling to predict where electric fields will intersect in their heads. They do not yet have direct brain imaging evidence to prove that electrical interference is completely isolated to the subthalamic nucleus. Because this part of the brain is so small, the electric fields may have also affected neighboring brain areas that help control mood and cognitive function. Future studies will need to incorporate advanced brain scans to see exactly how treatments affect surrounding tissues.
Additionally, the study was designed to only measure immediately after a single 20-minute session, and three participants dropped out before completing both visits. Medical experts do not yet know how long the improvement in movement lasts after the first hour. “These early results are promising, so we are already working with our collaborators at Shanghai University of Sport Science, the UK and Germany to conduct a large-scale study applying multi-day stimulation sessions to induce long-lasting effects, to determine how long the effects last, what the intervals between treatments should be, and which patients are most likely to respond,” said Zhou Junhong, co-author of the paper.
If repeated treatments are proven to be safe and can provide sustained relief, this electrical technology could expand the options available for disease management. A purely external device could ultimately help patients delay the need for invasive brain surgery or serve as an additional tool in conjunction with traditional drug treatments. Although the technology remains experimental until longer and larger trials are completed, it is a very promising prospect.
The study, “Transcranial Temporal Interference Stimulation Targeting Subthalamic Regions for Motor Symptoms of Parkinson’s Disease: A Pilot, Randomized, Double-Blind, Sham-Controlled Crossover Study,” was published by Chenhao Yang, Yongxin Xu, Yichao Du, Xiaonan Shen, Tingting Li, Nan Chen, Yulian Zhu, Lingyan Huang, Jiaojiao Lu, Lu Li, Zhenyu Qian, Zhen Wang, Wolf Ziman, Nil Grossman, Brad Manners, Alvaro Pascual-Leone, Junhong Chou, Chenchen Zhang, and Yu Liu.
